Harrow (HROW) announced leadership changes at its wholly-owned subsidiary, ImprimisRx. Frank Mullery has been appointed as CEO and Bridseida Cruz has been appointed as Head of Quality of ImprimisRx. Most recently, Mullery served as President of Sintetica US, where he spearheaded the creation of the company’s U.S. subsidiary – taking it from concept to full commercialization, while successfully launching its first five sterile injectable products. Cruz is an executive with over 25 years of experience leading quality and operations in 503B outsourcing, pharmaceutical, and medical device organizations.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HROW:
- Harrow price target raised to $74 from $70 at B. Riley
- Harrow price target raised to $70 from $42 at Lake Street
- Harrow Health Secures New $40 Million Credit Facility
- Harrow Health’s Promising Growth Trajectory: Buy Rating Supported by Strategic Initiatives and Product Expansion
- Harrow Health’s Promising Growth Trajectory: Analyst Recommends ‘Buy’ Amid Strategic Revenue Projections and Product Enthusiasm